{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:49:03Z","timestamp":1772826543396,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12325-022-02046-z","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:03:16Z","timestamp":1645599796000},"page":"1784-1793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Defining Utility Values for Chorea Health States in Patients with Huntington\u2019s Disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-4902","authenticated-orcid":false,"given":"Daniel O.","family":"Claassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-2309","authenticated-orcid":false,"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-2211","authenticated-orcid":false,"given":"Debbie","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-7666","authenticated-orcid":false,"given":"Mo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinat","family":"Ribalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"2046_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. https:\/\/doi.org\/10.1038\/nrdp.2015.5.","journal-title":"Nat Rev Dis Primers"},{"key":"2046_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204\u201316. https:\/\/doi.org\/10.1038\/nrneurol.2014.24.","journal-title":"Nat Rev Neurol"},{"key":"2046_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0193-953x(05)70345-2","volume":"20","author":"MS Haddad","year":"1997","unstructured":"Haddad MS, Cummings JL. Huntington\u2019s disease. Psychiatr Clin N Am. 1997;20:791\u2013807. https:\/\/doi.org\/10.1016\/s0193-953x(05)70345-2.","journal-title":"Psychiatr Clin N Am"},{"key":"2046_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391. https:\/\/doi.org\/10.1002\/mds.25075.","journal-title":"Mov Disord"},{"key":"2046_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25:24\u201334. https:\/\/doi.org\/10.1111\/ene.13413.","journal-title":"Eur J Neurol"},{"key":"2046_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40271-018-0312-x","volume":"11","author":"EM Thorley","year":"2018","unstructured":"Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of llfe in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11:547\u201359. https:\/\/doi.org\/10.1007\/s40271-018-0312-x.","journal-title":"Patient"},{"key":"2046_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1399-0004.2011.01748.x","volume":"80","author":"AK Ho","year":"2011","unstructured":"Ho AK, Hocaoglu MB, European Huntington\u2019s Disease Network Quality of Life Working Group. Impact of Huntington\u2019s across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet. 2011;80:235\u20139. https:\/\/doi.org\/10.1111\/j.1399-0004.2011.01748.x.","journal-title":"Clin Genet"},{"key":"2046_CR8","unstructured":"XENAZINE\u00ae (tetrabenazine) [package insert] Fontaine-les-Dijon, France: Recipharm Fontaine SAS; Sept 2017."},{"key":"2046_CR9","unstructured":"Austedo\u00ae (deutetrabenazine) tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; 2021."},{"key":"2046_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0167-6296(96)00509-7","volume":"16","author":"H Bleichrodt","year":"1997","unstructured":"Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ. 1997;16:155\u201375. https:\/\/doi.org\/10.1016\/s0167-6296(96)00509-7.","journal-title":"J Health Econ"},{"key":"2046_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hec.688","volume":"11","author":"H Bleichrodt","year":"2002","unstructured":"Bleichrodt H. A new explanation for the difference between time trade-off utilities and standard gamble utilities. Health Econ. 2002;11:447\u201356. https:\/\/doi.org\/10.1002\/hec.688.","journal-title":"Health Econ"},{"key":"2046_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/0272989X04268955","volume":"24","author":"SM van Osch","year":"2004","unstructured":"van Osch SM, Wakker PP, van den Hout WB, Stiggelbout AM. Correcting biases in standard gamble and time tradeoff utilities. Med Decis Mak. 2004;24:511\u20137. https:\/\/doi.org\/10.1177\/0272989X04268955.","journal-title":"Med Decis Mak"},{"key":"2046_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11317060-000000000-00000","volume":"27","author":"DR Wright","year":"2009","unstructured":"Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics. 2009;27:713\u201323. https:\/\/doi.org\/10.2165\/11317060-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"2046_CR14","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v4.27356","author":"J Dorey","year":"2016","unstructured":"Dorey J, Clay E, Khemiri A, Belhadj A, Cubillo PT, Toumi M. The quality of life of Spanish patients with Huntington\u2019s disease measured with H-QoL-I and EQ-5D. J Mark Access Health Policy. 2016. https:\/\/doi.org\/10.3402\/jmahp.v4.27356.","journal-title":"J Mark Access Health Policy"},{"key":"2046_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-016-0575-7","volume":"15","author":"MR van Walsem","year":"2017","unstructured":"van Walsem MR, Howe EI, Ruud GA, Frich JC, Andelic N. Health-related quality of life and unmet healthcare needs in Huntington\u2019s disease. Health Qual Life Outcomes. 2017;15:6. https:\/\/doi.org\/10.1186\/s12955-016-0575-7.","journal-title":"Health Qual Life Outcomes"},{"key":"2046_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10198-019-01092-9","volume":"20","author":"A Hawton","year":"2019","unstructured":"Hawton A, Green C, Goodwin E, Harrower T. Health state utility values (QALY weights) for Huntington\u2019s disease: an analysis of data from the European Huntington\u2019s Disease Network (EHDN). Eur J Health Econ. 2019;20:1335\u201347. https:\/\/doi.org\/10.1007\/s10198-019-01092-9.","journal-title":"Eur J Health Econ"},{"key":"2046_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3111\/13696998.2011.598201","volume":"14","author":"J Lowin","year":"2011","unstructured":"Lowin J, Bergman A, Chaudhuri KR, et al. A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s disease in the UK. J Med Econ. 2011;14:584\u201393. https:\/\/doi.org\/10.3111\/13696998.2011.598201.","journal-title":"J Med Econ"},{"key":"2046_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1023\/a:1008903126315","volume":"9","author":"CS Palmer","year":"2000","unstructured":"Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for \u2018off-time\u2019 outcomes in the treatment of Parkinson\u2019s disease. Qual Life Res. 2000;9:819. https:\/\/doi.org\/10.1023\/a:1008903126315.","journal-title":"Qual Life Res"},{"key":"2046_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/ner.12474","volume":"19","author":"JB Pietzsch","year":"2016","unstructured":"Pietzsch JB, Garner AM, Marks WJ Jr. Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States. Neuromodulation. 2016;19:689\u201397. https:\/\/doi.org\/10.1111\/ner.12474.","journal-title":"Neuromodulation"},{"key":"2046_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198725923.001.0001","volume-title":"Measuring and valuing health benefits for economic evaluation","author":"J Brazier","year":"2016","unstructured":"Brazier J, Ratcliffe J, Saloman J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2016."},{"issue":"4","key":"2046_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14737167.2020.1779062","volume":"20","author":"AK Lugner","year":"2020","unstructured":"Lugner AK, Krabbe PFM. An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):331\u201342. https:\/\/doi.org\/10.1080\/14737167.2020.1779062.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02046-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:41:08Z","timestamp":1649331668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02046-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2046"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02046-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}